AOD-9604

What AOD-9604 Does

AOD-9604 (Advanced Obesity Drug, fragment 176-191) is a modified peptide fragment of human growth hormone. It consists of the last 16 amino acids of HGH (positions 176-191) with a tyrosine modification — isolating the lipolytic (fat-burning) activity of HGH while eliminating its growth-promoting, IGF-1-stimulating, and insulin-resistance-inducing effects.

The mechanisms that matter:

• Lipolysis stimulation — activates beta-3 adrenergic receptors on adipocytes, triggering the breakdown of stored triglycerides into free fatty acids and glycerol. This is the same mechanism by which HGH burns fat, isolated to a single peptide fragment
• Lipogenesis inhibition — reduces the conversion of circulating fatty acids back into stored fat. The body burns fat and resists re-storing it
• No IGF-1 stimulation — unlike full HGH, AOD-9604 does not increase IGF-1 levels. This means no growth effects (organ enlargement, cellular proliferation) and no cancer risk concerns associated with chronically elevated IGF-1
• No insulin resistance — the HGH fragment was specifically engineered to remove the diabetogenic activity. Clinical studies confirmed no impact on fasting glucose or insulin sensitivity
• No appetite effects — AOD-9604 does not suppress or increase appetite. It works purely on fat cell metabolism, not hunger signaling

Where AOD-9604 Fits

AOD-9604 occupies a unique niche. It is not a weight loss drug in the way GLP-1 agonists are weight loss drugs. The distinction matters:

Feature	AOD-9604	GLP-1 Drugs (Semaglutide, etc.)
Mechanism	Direct fat cell lipolysis	Central appetite suppression
Weight loss magnitude	Modest (2–5% body fat)	Dramatic (15–25% body weight)
Appetite suppression	None	Strong
Metabolic effects	None (neutral)	Significant (insulin, glucose, CV)
Side effects	Minimal	GI effects (nausea, diarrhea)
Route	Daily SC injection (fasted)	Weekly SC injection
Best for	Stubborn fat in lean people	Significant weight loss in overweight/obese
Cost	$60–100/month	$80–1,300/month

AOD-9604 is a scalpel. GLP-1 drugs are a chainsaw. Use the right tool for the job.

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	250–500 mcg per day
Timing	Morning, fasted (30+ min before food)
Route	Subcutaneous injection (abdomen preferred)
Cycle length	8–12 weeks on, 4 weeks off
Injection site	Abdomen — near the target fat area (local fat metabolism may be enhanced near injection site)

Dose Selection

Dose	Use Case
250 mcg/day	Standard dose, effective for most users
300 mcg/day	Common middle ground
500 mcg/day	Maximum studied dose, aggressive protocols

Start at 250 mcg/day. Clinical trials used doses up to 1 mg/day, but 250–500 mcg is the range where most research-grade users see results with minimal cost.

Fasting Requirement

This is the most important practical detail: AOD-9604 must be injected in a fasted state.

Insulin is the off-switch for lipolysis. When insulin is elevated (after eating), AOD-9604’s primary mechanism is suppressed. For maximum effect:

1. Inject immediately upon waking (before coffee with calories, before breakfast)
2. Wait at least 30 minutes before eating — 60 minutes is better
3. Black coffee and water are fine (no calories = no insulin spike)
4. If combining with fasted cardio, inject 30 minutes before the session

Reconstitution

For a 5 mg vial — add 2.5 mL bacteriostatic water:

Daily Dose	Volume to Draw
250 mcg	12.5 units on insulin syringe
300 mcg	15 units
500 mcg	25 units

Concentration: 2,000 mcg/mL. A 5 mg vial lasts 10–20 days depending on dose.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution.

Cycling

• Standard: 8–12 weeks on, 4 weeks off
• Extended: Some users run 12–16 weeks, particularly when stacking with an exercise program
• Rationale: Cycling prevents potential receptor desensitization and allows assessment of results. There is no strong evidence that continuous use is harmful, but the standard practice is to cycle

What to Expect

Realistic Expectations

AOD-9604 produces modest, targeted fat loss — not dramatic weight loss. Calibrate expectations:

• Weeks 1–2: No visible change. The peptide is working at the cellular level but fat loss takes time to become visible
• Weeks 3–4: Possible subtle changes in stubborn fat areas. Measurements may show 0.5–1 inch reduction in waist circumference
• Weeks 5–8: Visible improvement in body composition for users near target weight. Clothes fit differently. The “last 5 pounds” areas start responding
• Weeks 8–12: Maximum effect from the cycle. Total fat reduction is modest but targeted — think 2–5 pounds of pure fat in the right areas

Who sees the best results: People already at 15–20% body fat who can’t shift stubborn areas with diet and exercise alone. AOD-9604 is the finishing tool, not the primary tool.

Who is disappointed: People expecting GLP-1-level weight loss. If you need to lose 30+ pounds, AOD-9604 is the wrong tool. Use semaglutide or tirzepatide.

Optimizing Results

AOD-9604’s effects are maximized by the right context:

1. Caloric deficit or maintenance — AOD-9604 mobilizes fat, but if you’re in a caloric surplus, the body will re-store it. At minimum, maintain caloric balance
2. Fasted cardio — injecting before low-intensity cardio (walking, light cycling) maximizes fat oxidation. The peptide mobilizes fatty acids; cardio burns them
3. Adequate sleep — growth hormone and fat metabolism are linked to sleep quality. Poor sleep blunts lipolysis
4. Don’t eat immediately after — the 30–60 minute fasted window post-injection is critical

What the Research Says

AOD-9604 has clinical data but the evidence base is thinner than GLP-1 drugs:

Phase 2 obesity trial: A 12-week randomized controlled trial of AOD-9604 (oral formulation, 1 mg/day) in obese subjects showed 2.6 kg of fat loss vs placebo. The effect was statistically significant but modest compared to GLP-1 drugs. No changes in glucose, insulin, or IGF-1 were observed. Published in Regulatory Peptides.

Mechanism studies: In vitro and animal studies confirmed AOD-9604 stimulates lipolysis in human fat cells and inhibits lipogenesis. The effect is mediated through beta-3 adrenergic receptor activation on adipocytes. The fragment retains fat-metabolizing activity equivalent to full HGH without the growth or diabetogenic effects.

Safety profile: No adverse events above placebo were observed in clinical trials. Specific safety monitoring confirmed no changes in fasting glucose, insulin, HbA1c, IGF-1, or thyroid function. The safety profile is one of AOD-9604’s primary advantages.

Cartilage repair (secondary finding): AOD-9604 demonstrated cartilage repair properties in osteoarthritis models, with research progressing into human trials for joint health applications. This is unrelated to fat loss but represents an interesting secondary benefit.

Limitation: No Phase 3 trials were completed for weight loss. Development was discontinued after Phase 2 — not because of safety concerns, but because the fat loss magnitude was not competitive enough for the pharmaceutical market. The drug was too mild for pharma, which doesn’t mean it’s ineffective for individual users with modest goals.

Safety

Side Effects

AOD-9604 has one of the mildest side effect profiles of any fat loss compound:

Side Effect	Frequency	Notes
Injection-site redness	~5%	Minor, transient
Mild headache	~3%	Usually first few days
Stomach discomfort	~2%	May relate to fasted injection, not the peptide

No serious adverse events in any clinical study. No metabolic disruption. No hormonal changes. No cardiovascular effects. No appetite changes. No mood effects.

What AOD-9604 Does NOT Do

This matters for setting expectations:

• Does not suppress appetite — if overeating is the problem, AOD-9604 won’t help
• Does not increase muscle mass — it’s not anabolic. No IGF-1 stimulation
• Does not increase growth hormone — it’s a fragment, not a secretagogue
• Does not affect thyroid — no metabolic rate changes
• Does not cause insulin resistance — unlike full HGH

Do Not Use If

• Pregnant or breastfeeding
• Under 18
• Active cancer (theoretical concern with any growth-related peptide, though AOD-9604 does not stimulate IGF-1)

What Comes Next

• Need more significant weight loss? — Semaglutide or Tirzepatide for 15–25% body weight reduction
• Compare all options — Weight Loss Peptides Compared
• Explore other protocols matched to your goals in the Directory
• Use the Reconstitution Calculator for exact dosing math